Pilot trial of salbutamol in central core and multi-minicore diseases

Neuropediatrics

Volumn 35, Issue 5, 2004, Pages 262-266

  Messina, S ^a   Hartley, L ^a   Main, M ^a   Kinali, M ^a   Jungbluth, H ^a   Muntoni, F ^a   Mercuri, Eugenio ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

agonists; Central core disease; Multi minicore disease; Skeletal muscle; Therapeutic trial

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CENTRAL CORE DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FUNCTION TEST; HEART PALPITATION; HUMAN; MALE; MULTIMINICORE DISEASE; MUSCLE MASS; MUSCLE STRENGTH; MYOPATHY; PILOT STUDY; PRIORITY JOURNAL; SKELETAL MUSCLE; TREMOR;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOPATHY, CENTRAL CORE; PILOT PROJECTS; RANGE OF MOTION, ARTICULAR; RECOVERY OF FUNCTION;

EID: 8844266044     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821173     Document Type: Article

References (25)

1. Beenakker EAC, van der Hoeven JH, Fock JM, Maurits NM. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. Neuromuscul Disord 2001; 11: 441-446
2. Beitzel F, Gregorevic P, Ryall JG, Plant DR, Sillence MN, Lynch GS. Beta2-adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol 2003; 96: 1385-1392
3. Caruso JF, Signorile JF, Perry AC et al. The effects of albuterol and iso-kinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 1995; 27: 1471-1476
4. Criswell DS, Powers SK, Herb RA. Clenbuterol-induced fiber type transition in the soleus of adult rats. Eur J Appl Physiol Occup 1996; 74: 391-396
5. Dubowitz V. Muscle Disorders in Childhood. 2nd ed. London: WB Saunders, 1997: 135-142
6. Dupont-Vesteegden EE, Katz MS, McCarter RJ. Beneficial versus adverse affects of long-term use of clenbuterol in mdx mice. Muscle Nerve 1995; 18: 1447-1459
7. Ferreiro A, Estournet B, Chateau D et al. Multi-minicore disease-searching for boundaries: phenotype analysis of 38 cases. Ann Neurol 2000; 48: 745-757
8. Ferreiro A, Monnier N, Romero NB et al. A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. Ann Neurol 2002; 51: 750-757
9. Ferreiro A, Quijano-Roy S, Pichereau C et al. Mutation of the seleno-protein N gene, which is implicated in rigid spine muscular dystrophy, causes the classical phenotype of multi-minicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002; 71: 739-749
10. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK, Isfort RJ. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 2002; 25: 729-734
11. Jungbluth H, Sewry C, Brown SC, Manzur AY, Mercuri E, Bushby K, Rowe P, Johnson MA, Hughes I, Lelsey A, Dubowitz V, Muntoni F. Minicore myopathy in children: a clinical and histopathological study of 19 cases. Neuromuscul Disord 2000; 10: 264-273
12. Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R, Banks L, Manzur AY, Muntoni F. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002; 59: 609-610
13. Kissel JT, Mendell JR, Griggs RC, McDermott M, Tawil R, The FSH-DY group. Open-label clinical trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology 1998; 50: 1402-1406
14. Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC, Tawil R, The FSH-DY group. Randomised, double-bind, placebo-controlled trial of albuterol in facio-scapulohumeral dystrophy. Neurology 2001; 57: 1437-1440
15. Lynch GS, Hayes A, Campbell SP, Williams DA. Effects of beta2-agonist administration and exercise on contractile activation of skeletal muscle fibers. J Appl Physiol 1996; 81: 1610-1618
16. Maltin CA, Delday MI, Watson JS et al. Clenbuterol, a beta-adrenoreceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci 1993; 84: 651-654
17. Martineau L, Horan MA, Rothwell NJ et al. Salbutamol, a beta-adrenoreceptor agonist, increases skeletal muscle strength in young men. Clin Sci 1992; 83: 615-654
18. Monnier N, Romero NB, Lerale J et al. An autosomal dominant congenital myopathy with central cores and nemaline rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum Mol Genet 2000; 9: 2599-2608
19. Ryall JG, Plant DR, Gregorevic P, Sillence MN, Lynch GS. β2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol (Lond) 2004; 555: 175-188
20. Scott OM, Hyde SA, Goddard C et al. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 1982; 5: 291-301
21. Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain 1956; 79: 610-621
22. Signorile JF, Banovac K, Gomez M et al. Increased muscle strength in paralyzed patients after spinal cord injury: effect of beta-adrenergic agonist. Arch Phys Med Rehabil 1995; 76: 55-58
23. Zeman RJ, Peng H, Danon MJ, Etlinger JD. Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle. Muscle Nerve 2000; 23: 521-528
24. Zerres K, Rudnick-Schoneborn S. Natural history in proximal spinal muscular atrophy. Arch Neurol 1995; 52: 518-523
25. Zhang K, Hu P, Wang S, Feher JJ et al. Salbutamol changes the molecular and mechanical properties of canine skeletal muscle. J Physiol 1996; 496: 211-220